11.11.2024
Publications category: Infectious diseases
20.09.2024
Bioavailability of a novel sustained-release pellet formulation of 5-flucytosine in healthy-fed participants for use in patients with cryptococcal meningitis
08.07.2024
Skin pharmacokinetics of miltefosine in the treatment of post-kala-azar dermal leishmaniasis in South Asia
25.06.2024
Physiologically-based pharmacokinetic (PBPK) modeling to predict disease effects on 5-flucytosine pharmacokinetics (PK) in the context of a switch from an immediate release (IR) to a sustained release (SR) formulation.
25.06.2024
Physiologically based pharmacokinetic modelling to support design of microarray patches delivering antiretroviral drugs to HIV positive children.
25.06.2024
A circular PK/PD/PK model explains the exposure of bulevirtide and bile salts in adult patients with Hepatitis D
26.03.2024
Bioavailability of three novel oral, sustained-release pellets, relative to an immediate-release tablet containing 500 mg flucytosine: A randomized, open-label, crossover study in healthy volunteers
01.11.2023
Physiologically based pharmacokinetic (PBPK) modelling of cabotegravir (CAB) to support design of microarray patches (MAPs) for the treatment of HIV positive children
22.08.2023
Physiologically based pharmacokinetic (PBPK) modeling of the oral absorption of 5-flucytosine to support further development of a sustained-release formulation for the treatment of cryptococcal meningoencephalitis
14.06.2023
Lumenfantrine Exposure in Malnourished Children: PBPK Modeling Applied for Predictions and Dose Adjustments
14.06.2023